These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34394938)

  • 1. Apremilast monotherapy for palmoplantar pustulosis: Report of three cases.
    Marovt M; Marko PB
    SAGE Open Med Case Rep; 2021; 9():2050313X211034926. PubMed ID: 34394938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Refractory palmoplantar pustulosis succesfully treated with apremilast.
    Carrascosa de Lome R; Conde Montero E; de la Cueva Dobao P
    Dermatol Ther; 2020 Mar; 33(2):e13230. PubMed ID: 31981290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Similarity and difference between palmoplantar pustulosis and pustular psoriasis.
    Yamamoto T
    J Dermatol; 2021 Jun; 48(6):750-760. PubMed ID: 33650702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS).
    Wilsmann-Theis D; Kromer C; Gerdes S; Linker C; Magnolo N; Sabat R; Reich K; Mössner R
    J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):2045-2050. PubMed ID: 34077577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immediate response to apremilast in patients with palmoplantar pustulosis: a retrospective pilot study.
    Kato N; Takama H; Ando Y; Yanagishita T; Ohshima Y; Ohashi W; Akiyama M; Watanabe D
    Int J Dermatol; 2021 May; 60(5):570-578. PubMed ID: 33454961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apremilast in Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Meta-analysis.
    Spencer RK; Elhage KG; Jin JQ; Davis MS; Hakimi M; Bhutani T; Liao W
    Dermatol Ther (Heidelb); 2023 Feb; 13(2):437-451. PubMed ID: 36609960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
    Bissonnette R; Pariser DM; Wasel NR; Goncalves J; Day RM; Chen R; Sebastian M
    J Am Acad Dermatol; 2016 Jul; 75(1):99-105. PubMed ID: 27021239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HL-A antigens in patients with persistent palmoplantar pustulosis and pustular psoriasis.
    Karvonen J; Tiilikainen A; Lassus A
    Ann Clin Res; 1975 Apr; 7(2):112-5. PubMed ID: 1181975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apremilast in the Treatment of Plaque Psoriasis: Differential Use in Psoriasis.
    Gao JC; Wu AG; Contento MN; Maher JM; Cline A
    Clin Cosmet Investig Dermatol; 2022; 15():395-402. PubMed ID: 35300435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases.
    Mössner R; Thaci D; Mohr J; Pätzold S; Bertsch HP; Krüger U; Reich K
    Arch Dermatol Res; 2008 Mar; 300(3):101-5. PubMed ID: 18239925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interventions for chronic palmoplantar pustulosis.
    Obeid G; Do G; Kirby L; Hughes C; Sbidian E; Le Cleach L
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011628. PubMed ID: 31958161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the Efficacy and Safety of Apremilast and Methotrexate in Patients with Palmoplantar Psoriasis: A Randomized Controlled Trial.
    Kt S; Thakur V; Narang T; Dogra S; Handa S
    Am J Clin Dermatol; 2021 May; 22(3):415-423. PubMed ID: 33712987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methotrexate monotherapy versus methotrexate and apremilast combination therapy in the treatment of palmoplantar psoriasis: A prospective, randomised, assessor-blinded, comparative study.
    Hassanandani T; Panda M; Jena AK; Raj C
    Indian J Dermatol Venereol Leprol; 2023; 89(2):213-220. PubMed ID: 35841363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-19 Levels Are Increased in Palmoplantar Pustulosis and Reduced following Apremilast Treatment.
    Wolk K; Wilsmann-Theis D; Witte K; Brembach TC; Kromer C; Gerdes S; Ghoreschi K; Reich K; Mössner R; Sabat R
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options.
    Menter A; Van Voorhees AS; Hsu S
    Dermatol Ther (Heidelb); 2021 Dec; 11(6):1917-1929. PubMed ID: 34626330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Apremilast in the treatment of palmoplantar pustulosis : A case series].
    Frischhut N; Ratzinger G
    Hautarzt; 2021 Mar; 72(3):252-256. PubMed ID: 32876701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Keating GM
    Drugs; 2017 Mar; 77(4):459-472. PubMed ID: 28213862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review.
    Sanchez IM; Sorenson E; Levin E; Liao W
    Dermatol Ther (Heidelb); 2017 Dec; 7(4):425-446. PubMed ID: 29143230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apremilast for the treatment of palmo-plantar non-pustular psoriasis: A real-life single-center retrospective study.
    Pavia G; Gargiulo L; Cortese A; Valenti M; Sanna F; Borroni RG; Costanzo A; Narcisi A
    Dermatol Ther; 2022 Feb; 35(2):e15253. PubMed ID: 34877758
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.